Prospects of Targeting the Gastrin Releasing Peptide Receptor and Somatostatin Receptor 2 for Nuclear Imaging and Therapy in Metastatic Breast Cancer.

Autor: Simone U Dalm, Willemijne A M E Schrijver, Anieta M Sieuwerts, Maxime P Look, Angelique C J Ziel-van der Made, Vanja de Weerd, John W Martens, Paul J van Diest, Marion de Jong, Carolien H M van Deurzen

Publikováno v: PLoS ONE, Vol 12, Iss 1, p e0170536 (2017)

The gastrin releasing peptide receptor (GRPR) and the somatostatin receptor 2 (SSTR2) are overexpressed on primary breast cancer (BC), making them ideal candidates for receptor-mediated nuclear imaging and therapy. The aim of this study was to determ

Externí odkaz: https://doaj.org/article/51a1fb980777414da1dd4196c537c453

FOXA1 levels are decreased in pleural breast cancer metastases after adjuvant endocrine therapy, and this is associated with poor outcome

Autor: Rui Henrique, Annelot van Rossum, Jelle Wesseling, Marjolein Droog, Karianne Schuurman, Wilbert Zwart, Sabine C. Linn, Sofia Salta, Michel M. van den Heuvel, Willemijne A. M. E. Schrijver, Paul J. van Diest, Cathy B. Moelans, Carmen Jerónimo

Publikováno v: Molecular Oncology
Molecular Oncology, 12, 1884-1894
Molecular Oncology, 12(11), 1884. Elsevier
Molecular Oncology, Vol 12, Iss 11, Pp 1884-1894 (2018)
Molecular Oncology, 12, 11, pp. 1884-1894
Molecular Oncology, 12(11), 1884-1894. Elsevier

Contains fulltext : 200105.pdf (Publisher’s version ) (Open Access) Estrogen receptor-alpha (ERalpha)-positive breast cancer is often treated with antihormonal regimens. However, resistance to treatment is common, leading to metastatic disease. ERa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c07920c6d0d0be4e283c475e5e354099
https://research.tue.nl/en/publications/39e285b4-34f6-4e7b-a04f-a066fd0714fc

Response to A. Matikas et al

Autor: Cathy B. Moelans, Paul J. van Diest, Karijn P M Suijkerbuijk, Willemijne A. M. E. Schrijver, Elsken van der Wall

Publikováno v: Journal of the National Cancer Institute, 110(11), 1282. Oxford University Press

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d29ef774e51cf8c270a2e58a330116f6
https://pubmed.ncbi.nlm.nih.gov/29618043

Prospects of targeting the gastrin releasing peptide receptor and somatostatin receptor 2 for nuclear imaging and therapy in metastatic breast cancer

Autor: Willemijne A. M. E. Schrijver, Angelique C. van der Made, Paul J. van Diest, Anieta M. Sieuwerts, John W.M. Martens, Marion de Jong, Simone U. Dalm, Maxime P. Look, Carolien H.M. van Deurzen, Vanja de Weerd

Publikováno v: PLoS One (print), 12(1):e0170536. Public Library of Science
PLoS ONE [E], 12(1). Public Library of Science
PLoS ONE
PLoS ONE, Vol 12, Iss 1, p e0170536 (2017)

Background The gastrin releasing peptide receptor (GRPR) and the somatostatin receptor 2 (SSTR2) are overexpressed on primary breast cancer (BC), making them ideal candidates for receptor- mediated nuclear imaging and therapy. The aim of this study w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21191c127058e94ce1756ab29be0fcf1
https://dspace.library.uu.nl/handle/1874/349046

Progressive APOBEC3B mRNA expression in distant breast cancer metastases

Autor: Willemijne A. M. E. Schrijver, Paul J. van Diest, Cathy B. Moelans, Natalie D. ter Hoeve, Vanja de Weerd, Carolien H.M. van Deurzen, Simone U. Dalm, John W.M. Martens, Anieta M. Sieuwerts

Publikováno v: PLoS One (print), 12(1):e0171343. Public Library of Science
PLoS ONE, Vol 12, Iss 1, p e0171343 (2017)
PLoS ONE [E], 12(1), e0171343. Public Library of Science
PLoS ONE

markdownabstract__Background:__ APOBEC3B was recently identified as a gain-of-function enzymatic source of mutagenesis, which may offer novel therapeutic options with molecules that specifically target this enzyme. In primary breast cancer, APOBEC3B

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04021e9ac0b15020aa66d3f88a02b0a2
https://hdl.handle.net/1765/95798